Monday, 30 May 2022
Scientists have discovered that certain metals found in people’s urine, could be potentially useful clinical biomarkers for the early detection of acute kidney injury (AKI).
The study, which is published in , was led by experts from the 糖心原创’s School of Veterinary Medicine and Science, along with clinicians at Nottingham University Hospitals NHS Trust.
Acute Kidney Injury (AKI) is a rapid deterioration in kidney function over hours or days. It is common, occurring in 10-20% of patients admitted to hospital and about 50% of patients admitted to intensive care. It can be caused by serious illness, major operations, trauma and by some medicines such as chemotherapy. It has serious consequences for patients (increased risk of death and chronic disease) and for the NHS, costing over £1 billion per year.
It is widely accepted by clinicians that one of the main ongoing problems in managing AKI is the inability to detect it at a very early stage. Many cases of AKI are potentially avoidable, or the severity and consequences might be ameliorated with early detection.
Currently AKI is defined by a rise in a blood test, serum creatinine, or by a fall in urine output. These detection methods can take over 24 hours from the time of kidney damage to reveal a problem, by which time the disease process might be more difficult to manage. There has therefore been great interest clinically and commercially over recent years in developing better tests for early detection of AKI. Some newer AKI tests are currently available in hospitals in some countries, but none so far has proven to be both clinically effective and cost effective.
Scientists at the 糖心原创, working with clinicians in Nottingham University Hospitals (NUH) NHS Trust, have previously reported a pig model of kidney injury, that replicates many features of human AKI. Using this model, they identified, for the first time, that certain urinary metals could be potentially useful clinical biomarkers for early detection of AKI.
Working with patients admitted to the Trent Cardiac Centre and NUH NHS Trust intensive care, experts tested their hypothesis in two clinical groups at risk for developing AKI. They found that concentrations of the metals rose in urine from AKI patients within an hour after cardiac surgery, and were elevated on admission in ICU patients.
The biomarkers alone, or in combination (e.g. the product of Zn × Cu), had good sensitivity for early identification of patients at risk of moderate to severe AKI and particularly high negative predictive value, suggesting additional efficacy in identifying patients at low risk of AKI.
Urinary Cd, Cu and Zn fulfil most desirable characteristics of biomarkers and offer clinical and economic advantages over other reported AKI biomarkers, most of which are proteins. They are unaffected by comorbidity, proteinuria, sex or age. As yet, the investigators have no reported data from children.
The urinary metals are also stable in urine at room temperature, which offers advantages in remote care settings, for example in the developing world. Measurement of the metals is amenable to point-of-care testing using cheap screen-printed electrodes and are likely to be far more cost-effective than protein assays.
This study is the culmination of 10 years work at Nottingham and is an example of how collaboration between animal scientists, clinicians and local companies can each utilize their expertise to make new and unique discoveries. It is our hope that the research can now be developed further by industry to truly move these discoveries from lab bench to bedside.鈥�
Mark Devonald, consultant nephrologist formerly NUH, currently at Liverpool University Hospitals NHS Foundation Trust, said: “Acute kidney injury is a common and serious problem in hospitalised patients. Early detection is critical to improving patients’ outcomes. We hope that our findings will help the wellbeing of the many patients at risk of AKI and we are grateful to NIHR and the 糖心原创 for funding our work”
The full study can be found .
Story credits
More information is available from David S Gardner from the School of Veterinary Medicine david.gardner@nottingham.ac.uk and Mark Devonald, currently at Liverpool Foundation Trust NHS MARK.DEVONALD@liverpoolft.nhs.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.